vs
Ginkgo Bioworks Holdings, Inc.（DNA）与INTEST CORP（INTT）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是INTEST CORP的1.0倍（$33.4M vs $32.8M），INTEST CORP同比增速更快（-10.3% vs -23.8%），INTEST CORP自由现金流更多（$-1.6M vs $-47.7M），过去两年INTEST CORP的营收复合增速更高（4.9% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
INTEST CORP是面向全球半导体产业的专业测试设备供应商，主营研发、生产及销售热管理系统、测试接口硬件、晶圆处理工具等产品，客户覆盖晶圆制造厂、芯片设计企业及汽车、工业电子等下游领域。
DNA vs INTT — 直观对比
营收规模更大
DNA
是对方的1.0倍
$32.8M
营收增速更快
INTT
高出13.5%
-23.8%
自由现金流更多
INTT
多$46.1M
$-47.7M
两年增速更快
INTT
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $32.8M |
| 净利润 | — | $1.2M |
| 毛利率 | — | 45.4% |
| 营业利润率 | -211.9% | 3.9% |
| 净利率 | — | 3.8% |
| 营收同比 | -23.8% | -10.3% |
| 净利润同比 | — | -17.4% |
| 每股收益（稀释后） | $-1.41 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAINTT
| Q4 25 | $33.4M | $32.8M | ||
| Q3 25 | $38.8M | $26.2M | ||
| Q2 25 | $49.6M | $28.1M | ||
| Q1 25 | $48.3M | $26.6M | ||
| Q4 24 | $43.8M | $36.6M | ||
| Q3 24 | $89.0M | $30.3M | ||
| Q2 24 | $56.2M | $34.0M | ||
| Q1 24 | $37.9M | $29.8M |
净利润DNAINTT
| Q4 25 | — | $1.2M | ||
| Q3 25 | $-80.8M | $-938.0K | ||
| Q2 25 | $-60.3M | $-503.0K | ||
| Q1 25 | $-91.0M | $-2.3M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $-56.4M | $495.0K | ||
| Q2 24 | $-217.2M | $230.0K | ||
| Q1 24 | $-165.9M | $662.0K |
毛利率DNAINTT
| Q4 25 | — | 45.4% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | — | 42.6% | ||
| Q1 25 | — | 41.5% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 46.3% | ||
| Q2 24 | — | 40.6% | ||
| Q1 24 | — | 43.8% |
营业利润率DNAINTT
| Q4 25 | -211.9% | 3.9% | ||
| Q3 25 | -231.8% | -4.5% | ||
| Q2 25 | -132.1% | -3.3% | ||
| Q1 25 | -184.1% | -10.8% | ||
| Q4 24 | -236.3% | 5.7% | ||
| Q3 24 | -62.0% | 1.6% | ||
| Q2 24 | -396.7% | 1.0% | ||
| Q1 24 | -469.1% | 1.6% |
净利率DNAINTT
| Q4 25 | — | 3.8% | ||
| Q3 25 | -207.9% | -3.6% | ||
| Q2 25 | -121.6% | -1.8% | ||
| Q1 25 | -188.2% | -8.7% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | -63.3% | 1.6% | ||
| Q2 24 | -386.4% | 0.7% | ||
| Q1 24 | -437.3% | 2.2% |
每股收益（稀释后）DNAINTT
| Q4 25 | $-1.41 | $0.10 | ||
| Q3 25 | $-1.45 | $-0.08 | ||
| Q2 25 | $-1.10 | $-0.04 | ||
| Q1 25 | $-1.68 | $-0.19 | ||
| Q4 24 | $-1.91 | $0.13 | ||
| Q3 24 | $-1.08 | $0.04 | ||
| Q2 24 | $-4.23 | $0.02 | ||
| Q1 24 | $-3.32 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $14.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $103.6M |
| 总资产 | $1.1B | $151.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAINTT
| Q4 25 | $422.6M | $14.2M | ||
| Q3 25 | $495.5M | $16.2M | ||
| Q2 25 | $559.4M | $19.2M | ||
| Q1 25 | $325.3M | $22.0M | ||
| Q4 24 | $561.6M | $19.8M | ||
| Q3 24 | $616.2M | $18.0M | ||
| Q2 24 | $730.4M | $20.4M | ||
| Q1 24 | $840.4M | $27.3M |
总债务DNAINTT
| Q4 25 | — | — | ||
| Q3 25 | — | $4.9M | ||
| Q2 25 | — | $5.9M | ||
| Q1 25 | — | $6.9M | ||
| Q4 24 | — | $7.9M | ||
| Q3 24 | — | $9.0M | ||
| Q2 24 | — | $10.0M | ||
| Q1 24 | — | $11.0M |
股东权益DNAINTT
| Q4 25 | $508.6M | $103.6M | ||
| Q3 25 | $559.8M | $101.9M | ||
| Q2 25 | $613.0M | $102.6M | ||
| Q1 25 | $647.4M | $99.4M | ||
| Q4 24 | $716.1M | $99.8M | ||
| Q3 24 | $797.9M | $100.4M | ||
| Q2 24 | $833.1M | $99.5M | ||
| Q1 24 | $987.3M | $99.3M |
总资产DNAINTT
| Q4 25 | $1.1B | $151.3M | ||
| Q3 25 | $1.2B | $148.3M | ||
| Q2 25 | $1.2B | $149.7M | ||
| Q1 25 | $1.3B | $148.0M | ||
| Q4 24 | $1.4B | $152.3M | ||
| Q3 24 | $1.5B | $158.4M | ||
| Q2 24 | $1.6B | $160.6M | ||
| Q1 24 | $1.6B | $159.5M |
负债/权益比DNAINTT
| Q4 25 | — | — | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | — | 0.10× | ||
| Q1 24 | — | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $-1.0M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $-1.6M |
| 自由现金流率自由现金流/营收 | -142.8% | -4.7% |
| 资本支出强度资本支出/营收 | 0.0% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.82× |
| 过去12个月自由现金流最近4个季度 | — | $5.7M |
8季度趋势，按日历期对齐
经营现金流DNAINTT
| Q4 25 | $-47.7M | $-1.0M | ||
| Q3 25 | $-31.6M | $3.5M | ||
| Q2 25 | $-40.3M | $-688.0K | ||
| Q1 25 | $-51.5M | $5.5M | ||
| Q4 24 | $-42.4M | $2.6M | ||
| Q3 24 | $-103.5M | $4.2M | ||
| Q2 24 | $-84.4M | $-5.1M | ||
| Q1 24 | $-89.3M | $2.1M |
自由现金流DNAINTT
| Q4 25 | $-47.7M | $-1.6M | ||
| Q3 25 | — | $3.1M | ||
| Q2 25 | $-40.3M | $-1.1M | ||
| Q1 25 | $-59.1M | $5.3M | ||
| Q4 24 | $-56.1M | $2.4M | ||
| Q3 24 | $-118.6M | $3.7M | ||
| Q2 24 | $-111.4M | $-5.4M | ||
| Q1 24 | $-96.0M | $1.7M |
自由现金流率DNAINTT
| Q4 25 | -142.8% | -4.7% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | -81.2% | -4.1% | ||
| Q1 25 | -122.4% | 19.9% | ||
| Q4 24 | -128.0% | 6.6% | ||
| Q3 24 | -133.2% | 12.4% | ||
| Q2 24 | -198.2% | -15.9% | ||
| Q1 24 | -252.9% | 5.8% |
资本支出强度DNAINTT
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.1% | 1.6% | ||
| Q1 25 | 15.8% | 0.9% | ||
| Q4 24 | 31.3% | 0.4% | ||
| Q3 24 | 16.9% | 1.7% | ||
| Q2 24 | 48.1% | 0.9% | ||
| Q1 24 | 17.7% | 1.1% |
现金转化率DNAINTT
| Q4 25 | — | -0.82× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.72× | ||
| Q3 24 | — | 8.58× | ||
| Q2 24 | — | -22.13× | ||
| Q1 24 | — | 3.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
INTT
| Environmental Technologies | $8.3M | 25% |
| Semiconductor Market | $6.9M | 21% |
| Thermal Testing Products | $6.4M | 19% |
| Service And Other Products | $4.8M | 15% |
| Oem Integrators And Distributor | $3.5M | 11% |
| Semiconductor Production Test Products | $3.0M | 9% |
